TISSUE REGENIX LIMITED

Active United Kingdom

Other research and experimental development on natural sciences and engineering

9 employees website.com
Life sciences and medical technology Other research and experimental development on natural sciences and engineering
T

TISSUE REGENIX LIMITED

Other research and experimental development on natural sciences and engineering

Founded 5 May 2006 Active United Kingdom 9 employees website.com
Life sciences and medical technology Other research and experimental development on natural sciences and engineering
Accounts Submitted 20 Aug 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 24 Apr 2026 Next due 5 May 2027 12 months remaining
Net assets £-17M £414K 2024 year on year
Total assets £43M £40K 2024 year on year
Total Liabilities £61M £374K 2024 year on year
Charges 6
6 outstanding

Contact & Details

Contact

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for TISSUE REGENIX LIMITED (05807272), an active life sciences and medical technology company based in United Kingdom. Incorporated 5 May 2006. Other research and experimental development on natural sciences and engineering. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2014–2024)

Cash in Bank

£38.00k

Increased by £14.00k (+58%)

Net Assets

-£17.07M

Increased by £414.00k (+2%)

Total Liabilities

£60.55M

Decreased by £374.00k (-1%)

Turnover

N/A

Employees

9

Debt Ratio

139%

Decreased by 1 (-1%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 6,500 Shares £6.50m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
9 Aug 20176,500£6.50m£1k

Officers

Officers

1 active 2 resigned
Status
Jonathan Martin GlennDirectorBritishUnited Kingdom573 Dec 2020Active

Shareholders

Shareholders (1)

Tissue Regenix Group Plc
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Group Structure

Group Structure

TISSUE REGENIX LIMITED Current Company
TRX VASCULAR LIMITED united kingdom
TRX CARDIAC LIMITED united kingdom
TRX WOUND CARE LIMITED united kingdom

Charges

Charges

6 outstanding

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
24 Apr 2026Confirmation StatementConfirmation statement made on 21 Apr 2026 with no updates
7 Jan 2026MortgageMortgage Create With Deed With Charge Number Charge Creation Date
3 Nov 2025OfficersTermination of Daniel Ray Lee as director on 15 Oct 2025
3 Nov 2025OfficersAppointment of Miss Kirsten Mary Lund as director on 16 Oct 2025
11 Sept 2025OfficersTermination of Jonathan Martin Glenn as director on 5 Sept 2025
24 Apr 2026 Confirmation Statement

Confirmation statement made on 21 Apr 2026 with no updates

7 Jan 2026 Mortgage

Mortgage Create With Deed With Charge Number Charge Creation Date

3 Nov 2025 Officers

Termination of Daniel Ray Lee as director on 15 Oct 2025

3 Nov 2025 Officers

Appointment of Miss Kirsten Mary Lund as director on 16 Oct 2025

11 Sept 2025 Officers

Termination of Jonathan Martin Glenn as director on 5 Sept 2025

Recent Activity

Latest Activity

Confirmation statement made on 21 Apr 2026 with no updates

1 weeks ago on 24 Apr 2026

Mortgage Create With Deed With Charge Number Charge Creation Date

3 months ago on 7 Jan 2026

Termination of Daniel Ray Lee as director on 15 Oct 2025

6 months ago on 3 Nov 2025

Appointment of Miss Kirsten Mary Lund as director on 16 Oct 2025

6 months ago on 3 Nov 2025

Termination of Jonathan Martin Glenn as director on 5 Sept 2025

7 months ago on 11 Sept 2025